Here are relevant reports on : stem-cells-market
-
Neuroblastoma Cancer Market by Diagnostics (MIBG Scan, Imaging, Urine Analysis, Biopsy), Treatment (Surgery, Chemotherapy, Radiation therapy, Stem Cell Transplant, Immunotherapy), Staging, Pipeline, Regulatory, Reimbursement - Global Forecast to 2021
Neuroblastoma is a rare extracranial solid tumor cancer that develops from immature nerve cells found in several areas of the body. It is the most common extracranial solid tumor in childhood.
- Published: May 2026
- Price: $ 4950
- TOC Available:
-
Cell Harvesting Market by Type (Manual, Automated), Application (Biopharmaceutical, Stem Cell Research), End User (Biotechnology, Biopharmaceutical Companies, Research Institute), and Region (North America, Europe, APAC, Row) - Global Forecasts to 2023
The global cell harvesting market is expected to reach USD 324.5 Million by 2023, at a CAGR of 8.7%. Some of the major players operating in the cell harvesting market are PerkinElmer (US), Brandel (US), TOMTEC (US), Cox Scientific (UK), Connectorate (Switzerland), Scinomix (US), ADSTEC (Japan), and Terumo BCT (a part of Terumo Corporation) (Japan).
- Published: March 2018
- Price: $ 4950
- TOC Available:
-
Exosome Research Market by Offering (Kits, Reagents (Antibodies, Isolation, Purification), Instruments, Services), Indication (Cancer, Infectious Diseases), Application (Biomarkers, Vaccines), Manufacturing Services (Stem Cell) - Global Forecast to 2030
The global exosome research market, valued at US$189.4 million in 2024, stood at US$214.4 million in 2025 and is projected to advance at a resilient CAGR of 17.5% from 2025 to 2030, culminating in a forecasted valuation of US$480.6 million by the end of the period. The growth of the Asia Pacific exosome research market is primarily due to the growing biomedical industry, increasing life science research, and rising investments by pharmaceutical & biotechnology companies in this region.
- Published: June 2025
- Price: $ 4950
- TOC Available:
-
Nerve Repair & Regeneration Market by Products (Neuromodulation Devices (Deep Brain Stimulation, Vagus Nerve Stimulation), Biomaterials (Nerve Conduits, Nerve Wraps), Application (Neurorrhaphy, Nerve Grafting, Stem Cell Therapy) & Region - Global Forecast to 2027
The global nerve repair market growth is primed to transition from $6.5 billion in 2022 to $11.6 billion by 2027, showcasing a strong CAGR of 12.1%. This growth is driven by the increasing prevalence of neurological disorders, rising geriatric population, high incidence of nerve injuries, and government support for neurological research.
- Published: May 2022
- Price: $ 4950
- TOC Available:
-
Stem Cell Therapy Market by Type (Allogeneic, Autologous), Cell Source (Adipose Tissue, Bone Marrow, Placenta/Umbilical Cord), Therapeutic Application (Musculoskeletal, Wounds, Surgeries, Inflammatory, Autoimmune, Cardiovascular) & Region - Global Forecast to 2028
The global stem cell therapy market, valued at US$259 million in 2022, stood at US$286 million in 2023 and is projected to advance at a resilient CAGR of 16.5% from 2023 to 2028, culminating in a forecasted valuation of US$615 million by the end of the period. Market growth is driven mainly by factors such as rise in funding for stem cell research, upsurge in the number of cell therapy production facilities that have GMP certification, and increased in the number of clinical trials associated with stem cell therapies.
- Published: December 2023
- Price: $ 4950
- TOC Available:
-
Cell Viability Assays Market by Product (MTT Assay, XTT Assay, Calcein, Resazurin, Flow Cytometry, Spectrophotometer), Cell Type (Human, Animal, Microbial), Application (Basic Research, Stem Cell, Discovery & Development) - Global Forecast to 2023
The global cell viability assays market is projected to reach USD 4.16 billion by 2023, growing at a CAGR of 8.4%. The prominent players in the cell viability assays market are Thermo Fisher Scientific (US), Bio-Rad Laboratories (US), Merck (Germany), GE Healthcare (US), BioTek Instruments (US), PerkinElmer (US), Promega Corporation (US), Biotium (US), Abcam plc (UK), Canvax (Spain), Abnova (Taiwan), G-Biosciences (US), Creative Bioarray (US), Danaher Corporation (US), and Becton, Dickinson and Company (US).
- Published: September 2018
- Price: $ 4950
- TOC Available:
-
Animal Stem Cell Therapy Market by Type (Allogeneic, Autologous), Species (Dog, Cat & Horse), End User (Veterinary Hospital, Research Organization) - Global Forecast to 2027
The global animal stem cell therapy market size is projected to reach USD 0.3 billion by 2027 from USD 0.2 million in 2022, at a CAGR of 5.2% during the forecast period. The growth in the cases of various health issues such as arthritis, degenerative joint disorders, and tendon injuries in animals. This factor is encouraging the development of the global animal stem cell therapy market.
- Published: May 2026
- Price: $ 4950
- TOC Available:
-
Stem Cell Assays Market Size by Type (Viability, Proliferation, Differentiation, Apoptosis), Cell Type (Mesenchymal, iPSCs, HSCs, hESCs), Product & Service (Instrument), Application (Regenerative Medicine, Clinical Research), End User - Global Forecast to 2027
The size of global stem cell assays market in terms of revenue was estimated to be worth USD 1.9 billion in 2022 and is poised to reach USD 4.5 billion by 2027, growing at a CAGR of 17.7% from 2022 to 2027. The research study consists of industry trends, pricing analysis, patent analysis, conference and webinar materials, key stakeholders, and buying behaviour in the market.
- Published: June 2022
- Price: $ 4950
- TOC Available:
-
Regenerative Medicine Market by Product (Stem Cell [Autologous, Allogenic], Immunotherapy, Gene Therapy, Tissue Engineering), Application (Musculoskeletal, Cancer, Dermatology, Wound care, Cardiovascular Diseases, Eye Disorders) & Region - Global Forecast to 2028
The global regenerative medicine market, valued at US$13.5 billion in 2022, stood at US$16.0 billion in 2023 and is projected to advance at a resilient CAGR of 25.1% from 2023 to 2028, culminating in a forecasted valuation of US$49.0 billion by the end of the period. The growth of this market is characterized by the increasing collaborations and partnerships by major market players, and the emerging applications in new therapeutic areas. Rising focus on personalized medicine and increasing regulatory approvals in regenerative medicine are also predicted to drive the market.
- Published: January 2024
- Price: $ 4950
- TOC Available:
-
Apoptosis Assays Market by Product (Caspase, Annexin V, DNA Fragmentation, Mitochondrial Assay), Detection Technology (Flow Cytometry, Florescence microscopy), Application (Stem Cell, Discovery & Development, Clinical Research) & Region - Global Forecasts to 2023
The global apoptosis assays market is projected to reach USD 5.9 billion by 2023, at a CAGR of 10.5%. The prominent players in the apoptosis assays market are Merck KGaA (Germany), Thermo Fisher Scientific (US), Bio-Rad Laboratories (US), Becton, Dickinson and Company (US), GE Healthcare (US), Sartorius AG (Germany), Danaher Corporation (US), Geno Technology (US), GeneCopoeia, Inc. (US), Bio-Techne Corporation(US), BioTek Instruments (US), PerkinElmer (US), Promega Corporation (US), Biotium (US), Abcam plc (UK), Canvax (Spain), Abnova (Taiwan), and Creative Bioarray (US).
- Published: November 2018
- Price: $ 4950
- TOC Available:
Records 21 to 30 of 50
